Kiniksa Competitors
| KNSA Stock | USD 44.96 0.29 0.65% |
Kiniksa Pharmaceuticals vs Zai Lab Correlation
Pay attention - limited upside
The correlation between Kiniksa Pharmaceuticals and ZLAB is -0.76 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Kiniksa Pharmaceuticals and ZLAB in the same portfolio, assuming nothing else is changed.
Moving together with Kiniksa Stock
Moving against Kiniksa Stock
| 0.73 | QSI | QuantumSi | PairCorr |
| 0.61 | EDIT | Editas Medicine | PairCorr |
| 0.61 | GNLX | Genelux Common | PairCorr |
| 0.61 | KRRO | Frequency Therapeutics | PairCorr |
| 0.61 | LYRA | Lyra Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kiniksa Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kiniksa Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Kiniksa Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Kiniksa and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Kiniksa Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Kiniksa Stock performing well and Kiniksa Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kiniksa Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IDYA | 1.93 | 0.08 | 0.03 | 0.14 | 2.06 | 4.86 | 10.56 | |||
| SRRK | 2.90 | 0.80 | 0.27 | 1.16 | 2.40 | 5.92 | 31.68 | |||
| APLS | 2.99 | (0.27) | 0.00 | (0.30) | 0.00 | 5.01 | 31.01 | |||
| VCYT | 2.49 | 0.10 | 0.05 | 0.10 | 2.67 | 5.74 | 36.91 | |||
| CPRX | 1.42 | 0.23 | 0.12 | 0.88 | 1.54 | 3.00 | 10.89 | |||
| FOLD | 1.54 | 0.77 | 0.64 | 2.32 | 0.00 | 3.45 | 30.77 | |||
| ADPT | 3.06 | 0.22 | 0.05 | 0.39 | 3.88 | 9.94 | 29.55 | |||
| MLYS | 2.43 | (0.36) | 0.00 | (0.25) | 0.00 | 5.87 | 24.81 | |||
| CDTX | 4.25 | 1.83 | 0.66 | (1.18) | 1.30 | 5.93 | 105.72 | |||
| ZLAB | 1.88 | (0.65) | 0.00 | (2.30) | 0.00 | 4.56 | 10.32 |
Cross Equities Net Income Analysis
Compare Kiniksa Pharmaceuticals and related stocks such as Ideaya Biosciences, Scholar Rock Holding, and Apellis Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (10.8 M) | (46.5 M) | (27.1 M) | (51 M) | (127.5 M) | (304.7 M) | (344.9 M) | (746.4 M) | (652.2 M) | (528.6 M) | (197.9 M) | (178.1 M) | (187 M) |
| VCYT | (14.4 M) | (14.4 M) | (18.6 M) | (25.6 M) | (29.4 M) | (33.7 M) | (31.4 M) | (31 M) | (23 M) | (12.6 M) | (34.9 M) | (75.6 M) | (36.6 M) | (74.4 M) | 24.1 M | 21.7 M | 22.8 M |
| CPRX | (255.9 K) | (6.4 M) | (4.1 M) | (12.2 M) | (15.5 M) | (20.2 M) | (18.1 M) | (18.4 M) | (34 M) | 31.9 M | 75 M | 39.5 M | 83.1 M | 71.4 M | 163.9 M | 188.5 M | 197.9 M |
| FOLD | (6.8 M) | (44.4 M) | (48.8 M) | (59.6 M) | (68.9 M) | (132.1 M) | (200 M) | (284 M) | (349 M) | (356.4 M) | (276.9 M) | (250.5 M) | (236.6 M) | (151.6 M) | (56.1 M) | (50.5 M) | (53 M) |
| ADPT | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (46.4 M) | (68.6 M) | (146.2 M) | (207.3 M) | (200.2 M) | (225.2 M) | (159.5 M) | (143.5 M) | (150.7 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (177.8 M) | (160 M) | (152 M) |
| CDTX | (792 K) | (792 K) | (792 K) | (1.3 M) | (11.9 M) | (32.2 M) | (48.2 M) | (55.7 M) | (59 M) | (41.1 M) | (72.1 M) | (43.9 M) | (29.8 M) | (22.9 M) | (169.8 M) | (152.8 M) | (145.2 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
Kiniksa Pharmaceuticals and related stocks such as Ideaya Biosciences, Scholar Rock Holding, and Apellis Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Kiniksa Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Kiniksa Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Kiniksa Pharmaceuticals Competitive Analysis
The better you understand Kiniksa Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Kiniksa Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Kiniksa Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Kiniksa Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Kiniksa Pharmaceuticals Competition
Kiniksa Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Kiniksa Pharmaceuticals in relation to its competition. Kiniksa Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Kiniksa Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Kiniksa Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Kiniksa Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Kiniksa Pharmaceuticals position
In addition to having Kiniksa Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hybrid Mix Funds Thematic Idea Now
Hybrid Mix Funds
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Kiniksa Pharmaceuticals Correlation with its peers. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. Expected growth trajectory for Kiniksa significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kiniksa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 5.5 | Earnings Share 0.45 | Revenue Per Share | Quarterly Revenue Growth 0.612 | Return On Assets |
Investors evaluate Kiniksa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Kiniksa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Kiniksa Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Kiniksa Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kiniksa Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Kiniksa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.